Aim immunotech announces abstract entitled, negative impact of paclitaxel on human breast tumor microenvironment and its reversal by the combination of interferon-Α with tlr3 agonist rintatolimod, (ampligen®), accepted for poster presentation by roswell park comprehensive cancer center at the aacr 2022 annual meeting

Ocala, fla., march 24, 2022 (globe newswire) -- aim immunotech inc. (nyse: american aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including covid-19, the disease caused by the sars-cov-2 virus, announced today that research led by roswell park comprehensive cancer center medical oncologist  shipra gandhi, md , has been accepted for poster presentation at the american association for cancer research (aacr) annual meeting 2022, being held april 8-13, 2022, in new orleans, louisiana.
AIM Ratings Summary
AIM Quant Ranking